Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2021)

Historic Capital Expenditures for Spero Therapeutics (SPRO) over the last 6 years, with Q4 2021 value amounting to -$39000.0.

  • Spero Therapeutics' Capital Expenditures fell 42500.0% to -$39000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $24000.0, marking a year-over-year decrease of 8471.34%. This contributed to the annual value of -$39000.0 for FY2021, which is 12484.08% down from last year.
  • According to the latest figures from Q4 2021, Spero Therapeutics' Capital Expenditures is -$39000.0, which was down 42500.0% from $12000.0 recorded in Q4 2020.
  • Spero Therapeutics' 5-year Capital Expenditures high stood at $2.4 million for Q4 2018, and its period low was -$39000.0 during Q4 2021.
  • In the last 5 years, Spero Therapeutics' Capital Expenditures had a median value of $51000.0 in 2020 and averaged $258636.4.
  • As far as peak fluctuations go, Spero Therapeutics' Capital Expenditures soared by 24150000.0% in 2018, and later crashed by 42500.0% in 2021.
  • Spero Therapeutics' Capital Expenditures (Quarter) stood at -$1000.0 in 2017, then skyrocketed by 241500.0% to $2.4 million in 2018, then crashed by 94.66% to $129000.0 in 2019, then crashed by 90.7% to $12000.0 in 2020, then tumbled by 425.0% to -$39000.0 in 2021.
  • Its Capital Expenditures stands at -$39000.0 for Q4 2021, versus $12000.0 for Q4 2020 and $51000.0 for Q3 2020.